The company states: “Zentalis Pharmaceuticals announced the presentation of final results from a Phase 1 trial of azenosertib and gemcitabine in relapsed or refractory osteosarcoma at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
- Zentalis price target lowered to $40 from $46 at H.C. Wainwright
- Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
- Zentalis announces anticipated upcoming milestones
- Zentalis sees cash runway into mid-2026